繁體
简体中文
繁體中文

再生元製藥公司 REGN 深 滬

已收盤 11-20 16:00:00 美东时间

920.69

-1.710

-0.19%

华盛通華盛通
立即下載
  • 最 高948.42
  • 今 開935.80
  • 成交量 87.83万股
  • 最 低 916.66
  • 昨 收 922.40
  • 總市值 952.43亿
  • 52周最高 991.73
  • 市盈率 靜 22.20
  • 換手率 0.85%
  • 52周最低 590.58
  • 委 比 3.03%
  • 總股本 1.03亿
  • 歷史最高 1204.8599
  • 量 比 1.04
  • 振 幅 3.44%
  • 歷史最低 36.49
  • 每 手 1
  • 風險率 75.82%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Alnylam Pharmaceuticals (ALNY) Wins FDA Approval in Myasthenia Gravis With Seventh RNAi Drug

    Alnylam Pharmaceuticals (NasdaqGS: ALNY) and Regeneron received FDA approval for Livsayis (cemdisiran) to treat generalized myasthenia gravis. Livsayis is the first RNAi-based therapy cleared in the United States for generalized myasthenia gravis, expanding Alnylam's disease reach. The decision makes Livsayis the seventh FDA-approved RNAi therapeutic built on Alnylam's platform within roughly nine years. This approval of Livsayis for generalized

    11-21 19:09

  • What Regeneron Pharmaceuticals Doubters Got Wrong

    Regeneron Pharmaceuticals spent this past year stacking fresh deals and clinical milestones, from the Telix radiopharmaceutical tie‑up to FDA approval of Livsayis for generalized myasthenia gravis. Investors who held Regeneron Pharmaceuticals over the past year are up 25.9%, including dividends. If you were deciding whether to buy on 19 November 2025, you would have seen that bullish and bearish analysts were 31% apart on fair value. Which story

    11-21 02:08

  • 3 AI Pharma Stocks Retail Investors Are Watching for R&D Efficiency

    AI is starting to reshape how big pharma searches for the next blockbuster drug, and that shift is pulling fresh attention to a handful of companies that talk openly about using algorithms, machine learning and computational chemistry in their pipelines. If you care about where capital may cluster next, ignoring this theme risks missing a potential re-rating story. This article unpacks three AI-exposed giants from the screener and explains why th

    11-20 22:09

  • Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm

    On CNBC’s “Mad Money Lightning Round,” Jim Cramer said UiPath Inc. (NYSE:PATH) is a “cheap, cheap stock, but it has no catalyst, so I have to vote it off the island.” UiPath said it will report third-quarter fiscal 2027 financial results after the closing bell on Thursday, Dec. 3. Karman Holdings In...

    11-20 20:52

  • 赛诺菲考虑发起制药行业数年来规模最大并购之一

    (来源:欧洲并购与投资) 赛诺菲考虑发起制药行业数年来规模最大并购之一 图片来源于网络 法国制药企业赛诺菲(Sanofi)上个月释放出扩大业务发展和...

    11-20 11:01

  • FDA Approval Could Be A Big Moment For Regeneron Stock (REGN)

    Regeneron Pharmaceuticals received past FDA approval for Livsayis (cemdisiran) to treat anti acetylcholine receptor antibody positive generalized myasthenia gravis in adults, based on Phase 3 NIMBLE data showing clinically meaningful gains on MG ADL and QMG scores with quarterly subcutaneous dosing. This first siRNA therapy in generalized myasthenia gravis gives Regeneron a new rare disease franchise that is fully owned, siRNA based, and supporte

    11-19 13:13

  • Regeneron Advances Early Blood-Disorder Study as REGN17235 Trial Recruits

    Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical...

    11-19 00:32

  • Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

    Regeneron's Livsayis, an siRNA therapy targeting complement component C5, has been approved by the FDA for treating anti-AChR antibody-positive generalized myasthenia gravis (gMG) in adults. It reduces C5 protein levels, inhibiting terminal complement activation and offering rapid, deep, and sustained disease control with four annual subcutaneous doses. Phase 3 NIMBLE trial results showed significant improvements in MG-ADL and QMG scores, with 76...

    11-18 23:03

  • 再生元制药收涨0.56%,成交额8.88亿美元

    11月18日,再生元制药(REGN)收涨0.56%,报957.76美元,成交额8.88亿美元,市值990.78亿美元。 行情数据 • 开盘价:952.56美元...

    11-18 05:33